Porter, L. H.
Zhu, J. J. http://orcid.org/0000-0003-4416-7040
Lister, N. L.
Harrison, S. G.
Keerthikumar, S.
Goode, D. L.
Urban, R. Quezada
Byrne, D. J.
Azad, A. http://orcid.org/0000-0001-7350-5622
Vela, I.
Hofman, M. S.
Neeson, P. J. http://orcid.org/0000-0002-2729-5887
Darcy, P. K. http://orcid.org/0000-0002-5303-9561
Trapani, J. A.
Taylor, R. A. http://orcid.org/0000-0003-2609-2380
Risbridger, G. P. http://orcid.org/0000-0003-3089-4028
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1102752, APP1136680, APP1102752, APP2011391)
Victorian Cancer Agency (MCRF15023)
Movember Foundation
Cancer Council Victoria (TP834128)
Article History
Received: 6 September 2022
Accepted: 11 August 2023
First Online: 2 September 2023
Competing interests
: G.P.R. and R.A.T. (Research collaborations: Pfizer, Astellas, Zenith Epigenetics, AstraZeneca); P.K.D. (Research funding from Myeloid Therapeutics, Prescient Therapeutics, and Bristol Myers Squibb); A.A. (Speakers Bureau: Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb; Merck Serono, Bayer; Honoraria: Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, Merck Sharpe Dome; Scientific Advisory Board: Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen, Noxopharm; Travel + Accommodation: Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer; Investigator Research Funding: Astellas, Merck Serono, AstraZeneca; Institutional Research Funding: Bristol Myers Squibb, AstraZeneca, Aptevo Therapeutics, Glaxo Smith Kline, Pfizer, MedImmune, Astellas, SYNthorx, Bionomics, Sanofi Aventis, Novartis, Ipsen); M.S.H. (personal fees for lectures or advisory boards: Jannsen, Mundipharma, Astellas, Merck/MSD, Astra Zeneca, Point Biopharma; Research support paid to institution: Endocyte and Advanced Accelerator Applications, both Novartis companies); I.V. (Honoraria: Astellas, Abbvie, Tolmar, Janssen; Scientific Advisory Board: Astellas, AstraZeneca, Janssen, Bayer); P.J.N. (Research funding from BMS, Roche Genentech, MSD, Prescient Therapeutics, CRISPR Therapeutics, Allergan, Compugen); All other authors declare no competing interests.